Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

École Polytechnique de Montréal

$58,000.00

Coiled-coil assisted control of antibody quality, delivery and binding

EF 2021-22

Résumé
The market of therapeutic recombinant proteins is now dominated by monoclonal antibodies (mAbs). With more than 60 mAbs approved and more than 350 undergoing clinical trials, this market now exceeds 50 billion dollars. Due to the complexity of mAb mode of production, mAb manufacturing still represent a significant economic burden to the public health care system. On the one hand, in the biopharmaceutical industry, the lack of cost-effective and high-throughput engineering solutions to assess mAb critical quality attributes severely impedes the improvement of current manufacturing processes relying on cell culture. First and foremost, the assessment of mAb glycosylation, a post translational modification performed by the cells, is crucial as glycosylation directly influences mAb stability and therapeutic efficacy. On the other hand, in the clinic, the mode of administration of mAbs via intravenous route, also needs improvement (more likely via materials engineering) to achieve maximal therapeutic efficacy. Indeed, intravenous administration forces the use of huge doses, in turn leading to patient inconvenience and high medical treatment costs. The lack of an efficient and versatile approach to promote the sustained local delivery of mAbs, alone or in combination with other drugs, severely impedes the development and implementation of the next-generation therapeutics. The focus of my ongoing research program is to develop versatile and efficient engineering strategies to control recombinant protein quality and delivery. Over the past years, my team has made significant progress on addressing these issues: we spearheaded the use of a grafting strategy relying on two distinct peptides, i.e., the E and K coils, to design better biosensing assays and control the capture of bioactive proteins into hydrogels. Because of the importance of mAbs, we will focus the next 5 years specifically on this class of biomolecules. Our short-term objectives for this Discovery Grant are to: 1) Develop the biosensing and numerical tools to characterize mAb glycosylation, and thus create an enhanced process analytical technology for mAb biomanufacturing 2) Design tunable, self-assembled hydrogels for the controlled release of mAbs and other entities, hence addressing the needs of the industry for platforms delivering combined therapies. 3) Further refine our grafting and delivery technological platform by fine-tuning the E and K coil peptide sequences, extending the characterization of their interactions to support the short and long-term objectives of this program. Overall, this Discovery Grant Program will contribute to the training of 10 undergraduate and 4 PhD students. Attaining our research objectives will not only yield insight into the fundamentals of mAb glycosylation and controlled release but facilitate technology transfer to our Canadian industrial partners, ultimately leading to more efficient and cost- effective treatment to Canadians.
Programme
Discovery Grants Program - Individual
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
RGPIN-2020-07039
Name nom
De Crescenzo, Gregory
Department département
Génie chimique
Organization id
64
Institution établissement
École Polytechnique de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2021
Competition year année de concours
2020
Award amount
58000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Installment
inst:2
Partie
1
Nb partie
5
Application title
Coiled-coil assisted control of antibody quality, delivery and binding
Keyword
NSERC
Application summary
The market of therapeutic recombinant proteins is now dominated by monoclonal antibodies (mAbs). With more than 60 mAbs approved and more than 350 undergoing clinical trials, this market now exceeds 50 billion dollars. Due to the complexity of mAb mode of production, mAb manufacturing still represent a significant economic burden to the public health care system. On the one hand, in the biopharmaceutical industry, the lack of cost-effective and high-throughput engineering solutions to assess mAb critical quality attributes severely impedes the improvement of current manufacturing processes relying on cell culture. First and foremost, the assessment of mAb glycosylation, a post translational modification performed by the cells, is crucial as glycosylation directly influences mAb stability and therapeutic efficacy. On the other hand, in the clinic, the mode of administration of mAbs via intravenous route, also needs improvement (more likely via materials engineering) to achieve maximal therapeutic efficacy. Indeed, intravenous administration forces the use of huge doses, in turn leading to patient inconvenience and high medical treatment costs. The lack of an efficient and versatile approach to promote the sustained local delivery of mAbs, alone or in combination with other drugs, severely impedes the development and implementation of the next-generation therapeutics. The focus of my ongoing research program is to develop versatile and efficient engineering strategies to control recombinant protein quality and delivery. Over the past years, my team has made significant progress on addressing these issues: we spearheaded the use of a grafting strategy relying on two distinct peptides, i.e., the E and K coils, to design better biosensing assays and control the capture of bioactive proteins into hydrogels. Because of the importance of mAbs, we will focus the next 5 years specifically on this class of biomolecules. Our short-term objectives for this Discovery Grant are to: 1) Develop the biosensing and numerical tools to characterize mAb glycosylation, and thus create an enhanced process analytical technology for mAb biomanufacturing 2) Design tunable, self-assembled hydrogels for the controlled release of mAbs and other entities, hence addressing the needs of the industry for platforms delivering combined therapies. 3) Further refine our grafting and delivery technological platform by fine-tuning the E and K coil peptide sequences, extending the characterization of their interactions to support the short and long-term objectives of this program. Overall, this Discovery Grant Program will contribute to the training of 10 undergraduate and 4 PhD students. Attaining our research objectives will not only yield insight into the fundamentals of mAb glycosylation and controlled release but facilitate technology transfer to our Canadian industrial partners, ultimately leading to more efficient and cost- effective treatment to Canadians.